hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial

Arnold Melman, Natan Bar-Chama, Andrew McCullough, Kelvin Davies, George Christ

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a "naked" DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the α, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patients each were given 500,1000, and 5000 μg, and two patients were given 7500 μg, of hMaxi-K and monitored for 24 weeks. The primary objectives of this phase I study were safety and tolerability of escalating hMaxi-K doses as assessed by clinical evaluations and laboratory tests. Secondary efficacy objectives were measured primarily by use of the International Index of Erectile Function (IIEF) scale. Patient responses were validated by partner responses. There were no serious adverse events and no dose-related adverse events attributed to gene transfer for any patient at any dose or study visit. No clinically significant changes from baseline were seen in physical evaluations (general and genitourinary), hematology, chemistry, and hormone analyses, or in cardiac events evaluated by repeated electrocardiograms. Importantly, no plasmid was detected in the semen of patients at any time after the injections. Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One patient given 5000 μg and one given 7500 μg reported EF category improvements that were highly clinically significant and were also maintained through the 24 weeks of study. Efficacy conclusions cannot be drawn from results of a phase I trial with no control group. However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a viable approach to the treatment of ED and that further studies investigating the efficacy of hMaxi-K in patients with ED should be performed.

Original languageEnglish (US)
Pages (from-to)1165-1176
Number of pages12
JournalHuman Gene Therapy
Volume17
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Erectile Dysfunction
Genes
Plasmids
Large-Conductance Calcium-Activated Potassium Channels
Safety
Patient Transfer
Injections
Hematology
Semen
Smooth Muscle
Electrocardiography
Complementary DNA
Outcome Assessment (Health Care)
Hormones
Control Groups
DNA

ASJC Scopus subject areas

  • Genetics

Cite this

hMaxi-K gene transfer in males with erectile dysfunction : Results of the first human trial. / Melman, Arnold; Bar-Chama, Natan; McCullough, Andrew; Davies, Kelvin; Christ, George.

In: Human Gene Therapy, Vol. 17, No. 12, 12.2006, p. 1165-1176.

Research output: Contribution to journalArticle

Melman, Arnold ; Bar-Chama, Natan ; McCullough, Andrew ; Davies, Kelvin ; Christ, George. / hMaxi-K gene transfer in males with erectile dysfunction : Results of the first human trial. In: Human Gene Therapy. 2006 ; Vol. 17, No. 12. pp. 1165-1176.
@article{d25938befcfc46f1acdbe1bdf52f5074,
title = "hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial",
abstract = "Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a {"}naked{"} DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the α, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patients each were given 500,1000, and 5000 μg, and two patients were given 7500 μg, of hMaxi-K and monitored for 24 weeks. The primary objectives of this phase I study were safety and tolerability of escalating hMaxi-K doses as assessed by clinical evaluations and laboratory tests. Secondary efficacy objectives were measured primarily by use of the International Index of Erectile Function (IIEF) scale. Patient responses were validated by partner responses. There were no serious adverse events and no dose-related adverse events attributed to gene transfer for any patient at any dose or study visit. No clinically significant changes from baseline were seen in physical evaluations (general and genitourinary), hematology, chemistry, and hormone analyses, or in cardiac events evaluated by repeated electrocardiograms. Importantly, no plasmid was detected in the semen of patients at any time after the injections. Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One patient given 5000 μg and one given 7500 μg reported EF category improvements that were highly clinically significant and were also maintained through the 24 weeks of study. Efficacy conclusions cannot be drawn from results of a phase I trial with no control group. However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a viable approach to the treatment of ED and that further studies investigating the efficacy of hMaxi-K in patients with ED should be performed.",
author = "Arnold Melman and Natan Bar-Chama and Andrew McCullough and Kelvin Davies and George Christ",
year = "2006",
month = "12",
doi = "10.1089/hum.2006.17.1165",
language = "English (US)",
volume = "17",
pages = "1165--1176",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - hMaxi-K gene transfer in males with erectile dysfunction

T2 - Results of the first human trial

AU - Melman, Arnold

AU - Bar-Chama, Natan

AU - McCullough, Andrew

AU - Davies, Kelvin

AU - Christ, George

PY - 2006/12

Y1 - 2006/12

N2 - Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a "naked" DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the α, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patients each were given 500,1000, and 5000 μg, and two patients were given 7500 μg, of hMaxi-K and monitored for 24 weeks. The primary objectives of this phase I study were safety and tolerability of escalating hMaxi-K doses as assessed by clinical evaluations and laboratory tests. Secondary efficacy objectives were measured primarily by use of the International Index of Erectile Function (IIEF) scale. Patient responses were validated by partner responses. There were no serious adverse events and no dose-related adverse events attributed to gene transfer for any patient at any dose or study visit. No clinically significant changes from baseline were seen in physical evaluations (general and genitourinary), hematology, chemistry, and hormone analyses, or in cardiac events evaluated by repeated electrocardiograms. Importantly, no plasmid was detected in the semen of patients at any time after the injections. Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One patient given 5000 μg and one given 7500 μg reported EF category improvements that were highly clinically significant and were also maintained through the 24 weeks of study. Efficacy conclusions cannot be drawn from results of a phase I trial with no control group. However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a viable approach to the treatment of ED and that further studies investigating the efficacy of hMaxi-K in patients with ED should be performed.

AB - Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a "naked" DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the α, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patients each were given 500,1000, and 5000 μg, and two patients were given 7500 μg, of hMaxi-K and monitored for 24 weeks. The primary objectives of this phase I study were safety and tolerability of escalating hMaxi-K doses as assessed by clinical evaluations and laboratory tests. Secondary efficacy objectives were measured primarily by use of the International Index of Erectile Function (IIEF) scale. Patient responses were validated by partner responses. There were no serious adverse events and no dose-related adverse events attributed to gene transfer for any patient at any dose or study visit. No clinically significant changes from baseline were seen in physical evaluations (general and genitourinary), hematology, chemistry, and hormone analyses, or in cardiac events evaluated by repeated electrocardiograms. Importantly, no plasmid was detected in the semen of patients at any time after the injections. Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One patient given 5000 μg and one given 7500 μg reported EF category improvements that were highly clinically significant and were also maintained through the 24 weeks of study. Efficacy conclusions cannot be drawn from results of a phase I trial with no control group. However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a viable approach to the treatment of ED and that further studies investigating the efficacy of hMaxi-K in patients with ED should be performed.

UR - http://www.scopus.com/inward/record.url?scp=33845774784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845774784&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.1165

DO - 10.1089/hum.2006.17.1165

M3 - Article

C2 - 17134370

AN - SCOPUS:33845774784

VL - 17

SP - 1165

EP - 1176

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -